



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Gil Ben-Menachem et al.**Application No.:** 10/550,907**Filed:** September 27, 2005**Confirmation No.:** 4584**For:** CHOLESTEROL-CONTAINING
COMPOUNDS AND THEIR USE AS
IMMUNOGENS AGAINST BORRELIA
BURGDORFERI**Examiner:** To be assigned**Art Unit:** 1636**Attorney Reference No.:** 4239-68220-03**CERTIFICATE OF MAILING**

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent
for Applicant(s)Date Mailed August 31, 2006MAIL STOP AMENDMENT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450**INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(b)(3)**

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language and/or non-English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.


Applicants filed this Information Disclosure Statement ("IDS") before the mailing date of a first Office action on the merits. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A **duplicate** copy of this Information Disclosure Statement is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.



Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By


Wayne W. Rupert
Registration No. 34,420

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 228-9446

INFORMATION DISCLOSURE STATEMENT BY APPLICANT  	Attorney Docket Number	4239-68220-03
	Application Number	10/550,907
	Filing Date	September 27, 2005
	First Named Inventor	Gil Ben-Menachem
	Art Unit	1636
	Examiner Name	To be assigned

Examiner's Office (optional)	Cite No. (optional)	OTHER DOCUMENTS
		Arving et al., "Antibodies to Cholesterol, Cholesterol Conjugates and Liposomes: Implications for Atherosclerosis and Autoimmunity," <i>Crit Rev. Immunol.</i> 10:441-453, 1991
		Anspach, "Endotoxin removal by affinity sorbents," <i>J. Biochem. Biophys. Methods</i> 49:665-681, 2001
		Asbrink et al., "The Spirochetal Etiology of Acrodermatitis chronica atrophicans Herxheimer," <i>Acta Derm Venerol (Stockh)</i> 64:506-512, 1984
		Barbour et al., "Antibodies of Patients with Lyme Disease to Components of the <i>Ixodes dammini</i> Spirochete," <i>The Journal of Clinical Investigation</i> 72:504-515, 1983
		Barbour et al., "A <i>Borrelia</i> -Specific Monoclonal Antibody Binds to a Flagellar Epitope," <i>Infection and Immunity</i> 52(5):549-554, 1986
		Barbour et al., "Biology of <i>Borrelia</i> Species," <i>Microbiological Reviews</i> 50(4):381-400, 1986
		Beck et al., "Chemical and Biological Characterization of a Lipopolysaccharide Extracted From the Lyme Disease Spirochete (<i>Borrelia burgdorferi</i>)," <i>The Journal of Infectious Diseases</i> 152(1):108-117, 1985
		Beck et al., "Isolation, Preliminary Chemical Characterization, and Biological Activity of <i>Borrelia burgdorferi</i> Peptidoglycan," <i>Biochemical and Biophysical Research Communications</i> 167(1):89-95, 1990
		Ben-Menachem et al., "Antibody response to MfGL-II, a phosphocholine-containing major lipid of <i>Mycoplasma fermentans</i> membranes," <i>FEMS Microbiology Letters</i> 154:363-369, 1997
		Bligh et al., "A Rapid Method of Total Lipid Extraction and Purification," <i>Canadian Journal of Biochemistry and Physiology</i> 37(8):911-917, 1959
		Bock et al., "A Study of ¹³ CH Coupling Constants in Pentopyranoses and Some of their Derivatives," <i>Acta Chemica Scandinavica B</i> 29(2):258-264, 1975
		Craft et al., "Antigens of <i>Borrelia burgdorferi</i> Recognized during Lyme Disease," <i>J. Clin. Invest.</i> 78:934-939, 1986
		Dell et al., "F.A.B.-Mass Spectrometry of Carbohydrates," <i>Advances in Carbohydrate Chemistry and Biochemistry</i> 45:19-72, 1987
		Habicht et al., "Lyme Disease Spirochetes Induce Human and Murine Interleukin 1 Production," <i>Journal of Immunology</i> 134(5):3147-3154, 1985
		Halter et al., "Lipooligosaccharides from <i>Treponema hyodysenteriae</i> and <i>Treponema innocens</i> ," <i>Infection and Immunity</i> 56(12):3152-3156, 1988

EXAMINER SIGNATURE:	DATE CONSIDERED:
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Attorney Docket Number	4239-68220-03
	Application Number	10/550,907
	Filing Date	September 27, 2005
	First Named Inventor	Gil Ben-Menachem
	Art Unit	1636
	Examiner Name	To be assigned

Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS
		Hirai et al., "Unique Cholesteryl Glucosides in <i>Helicobacter pylori</i> : Composition and Structural Analysis," <i>Journal of Bacteriology</i> 177(18):5327-5333, 1995
		Honarvar et al., "A 14,000 MW lipoprotein and a glycolipid-like structure of <i>Borrelia burgdorferi</i> induce proliferation and immunoglobulin production in mouse B cells at high frequencies," <i>Immunology</i> 82:389-396, 1994
		Lathrop et al., "Adverse event reports following vaccination for Lyme disease: December 1998-July 2000," <i>Vaccine</i> 20:1603-1608, 2002
		Livermore et al., "Lipid Metabolism of <i>Borrelia hermsi</i> ," <i>Infection and Immunity</i> 20(1):215-220, 1978
		Mayberry et al., "Structures and Properties of Acyl Diglucosylcholesterol and Galactofuranosyl Diacylglycerol from <i>Acholeplasma Axanthum</i> ," <i>Biochimica et Biophysica Acta</i> 752:434-443, 1983
		Orloski et al., "Surveillance for Lyme Disease – United States, 1992-1998," <i>MMWR Morbidity and Mortality Weekly Report CDC Surveillance Summary</i> 49(SS-3):1-30, 2000
		Paściak et al., "Structure of the major glycolipid from <i>Rothia dentocariosa</i> ," <i>Biochimica et Biophysica Acta</i> 1594:199-205, 2002
		Radolf et al., "Characterization of Outer Membranes Isolated from <i>Borrelia burgdorferi</i> , the Lyme Disease Spirochete," <i>Infection and Immunity</i> 63(6):2154-2163, 1995
		Rahn, "Vaccine Recommendations: Challenges and Controversies," <i>Infectious Disease Clinics of North America</i> 15(1):1-15, 2001
		Rasley et al., " <i>Borrelia burgdorferi</i> induces inflammatory mediator production by murine microglia," <i>Journal of Neuroimmunology</i> 130:22-31, 2002
		Razin, "Cholesterol Incorporation into Bacterial Membranes," <i>Journal of Bacteriology</i> 124(1):570-572, 1975
		Reich et al., "Nuclear Magnetic Resonance Spectroscopy. Carbon-13 Spectra of Steroids," <i>Journal of the American Chemical Society</i> 91(26):7445-7454, 1969
		Roth et al., "The Quantitative Determination of Galactose – An Enzymic Method Using Galactose Oxidase, with Applications to Blood and Other Biological Fluids," <i>Analytical Biochemistry</i> 10:32-52, 1965
		Rottem, "Sterols and Acylated Proteins in Mycoplasmas," <i>Biochemical and Biophysical Research Communications</i> 292(5):1289-1292, 2002
		Sadziene et al., "Experimental Immunization against Lyme Borreliosis with Recombinant Osp Proteins: An Overview," <i>Infection</i> 24(2):195-202, 1996

EXAMINER SIGNATURE:	DATE CONSIDERED:
------------------------	---------------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Attorney Docket Number	4239-68220-03
	Application Number	10/550,907
	Filing Date	September 27, 2005
	First Named Inventor	Gil Ben-Menachem
	Art Unit	1636
	Examiner Name	To be assigned

Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS
		Sawardeker et al., "Quantitative Determination of Monosaccharides as Their Alditol Acetates by Gas Liquid Chromatography," <i>Analytical Chemistry</i> 37:1602-1604, 1965
		Srimal et al., "Titration calorimetric studies to elucidate the specificity of the interactions of polymyxin B with lipopolysaccharides and lipid A," <i>Biochem. J.</i> 315:679-686, 1996
		Steere et al., "Chronic Lyme Arthritis. Clinical and Immunogenetic Differentiation from Rheumatoid Arthritis," <i>Annals of Internal Medicine</i> 90:896-901, 1979
		Steere et al., "Lyme Carditis: Cardiac Abnormalities of Lyme Disease," <i>Annals of Internal Medicine</i> 93(Part1):8-16, 1980
		Steere et al., "The Early Clinical Manifestations of Lyme Disease," <i>Annals of Internal Medicine</i> 99:76-82, 1983
		Steere et al., "The Spirochetal Etiology of Lyme Disease," <i>The New England Journal of Medicine</i> 308(13):733-740, 1983
		Steere, "Lyme Disease," <i>The New England Journal of Medicine</i> 345(2):115-125, 2001
		Takayama et al., "Absence of Lipopolysaccharide in the Lyme Disease Spirochete, <i>Borrelia burgdorferi</i> ," <i>Infection and Immunity</i> 55(9):2311-2313, 1987
		Vinh et al., "Characterization and Taxonomic Significance of Lipopolysaccharides of <i>Leptospira interrogans</i> Serovar <i>hardjo</i> ," <i>Journal of General Microbiology</i> 135:2663-2673, 1989
		Zähringer et al., "Primary Structure of a New Phosphocholine-containing Glycoglycerolipid of <i>Mycoplasma fermentans</i> ," <i>The Journal of Biological Chemistry</i> 272(42):26262-26270, 1997

EXAMINER SIGNATURE:	DATE CONSIDERED:
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Gil Ben- Menachem et al.

Application No.: 10/550,907

Filed: September 27, 2005

Confirmation No.: 4584

For: CHOLESTEROL-CONTAINING
COMPOUNDS AND THEIR USE AS
IMMUNOGENS AGAINST BORRELIA
BURGDORFERI

Examiner: To be assigned

Art Unit: 1636

Attorney Reference No.: 4239-68220-03

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent
for Applicant(s)

Wayne W. Rupert

Date Mailed August 31, 2006

MAIL STOP AMENDMENT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

TRANSMITTAL LETTER

Enclosed for filing in the application referenced above are the following:

- ☒ Supplemental Information Disclosure Statement
- ☒ Form PTO-1449 and references cited thereon
- ☒ The Director is hereby authorized to charge any additional fees that may be required, or credit over-payment, to Deposit Account No. 02-4550. A copy of this sheet is enclosed.
- ☒ Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

Wayne W. Rupert

Wayne W. Rupert

Registration No. 34,420

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 228-9446